WASHINGTON, D.C. — In a blow to Amgen Inc. and two subsidiaries, the Federal Circuit U.S. Court of Appeals on Feb. 11 upheld findings by a federal judge in Delaware that three claims of two patents that describe antibodies that purportedly lower low-density lipoprotein (LDL) cholesterol are invalid for their lack of enablement.
NEW YORK — A New York federal judge on Feb. 11 granted a motion by a union health benefit fund to certify a class of purchasers of the Alzheimer’s drug Namenda who were injured by a “pay-for-delay” scheme but denied certification of a class allegedly injured by being forced to switch from an original version of the drug to a newer one.
WASHINGTON, D.C. — In a two-page order issued Feb. 10, the Federal Circuit U.S. Court of Appeals announced that it will revisit its October 2020 finding that Teva Pharmaceuticals USA Inc. induced infringement of a reissue patent directed to the treatment of chronic heart failure.
WASHINGTON, D.C. — In a Feb. 10 holding, the Federal Circuit U.S. Court of Appeals said it found no error in an Illinois federal judge’s determination that a single claim of a patented golf club shape is invalid as indefinite, in a win for Nike Inc.
WASHINGTON, D.C. — In a Jan. 11 appellant brief, a patent owner tells the Federal Circuit U.S. Court of Appeals that its dispute with an alleged infringer presents “novel and critical” issues relating to the application of the enablement and definiteness requirements of one provision of federal patent law to a provision pertaining to patent eligibility.
WASHINGTON, D.C. — In a Jan. 8 appellant brief filed with the Federal Circuit U.S. Court of Appeals, the owner of a patent directed to a real time vehicle guidance system maintains that a federal judge in Delaware erred when deeming the disputed technology ineligible for patenting.
WASHINGTON, D.C. — Findings by the Patent Trial and Appeal Board that various proposed substitute claims in a patent reciting a system and method for permitting a customer in a loyalty program to redeem loyalty points are patent-eligible were rejected Feb. 8 by the Federal Circuit U.S. Court of Appeals.
ALEXANDRIA, Va. — In a Feb. 5 petition filed with the Patent Trial and Appeal Board, a beauty products company maintains that the board erred when it recently approved a continuation patent directed to eyelash extensions.
WASHINGTON, D.C. — In a Feb. 5 holding, the Federal Circuit U.S. Court of Appeals found no error in a determination by the U.S. Patent and Trademark Office (PTO) that a claimed method for countering credit card fraud recites ineligible subject matter.
WASHINGTON, D.C. — A federal judge in Washington did not abuse her discretion in denying a patent infringement defendant’s request for $630,318.91 in attorney fees, the Federal Circuit U.S. Court of Appeals concluded Feb. 4.
WASHINGTON, D.C. — In a Feb. 4 ruling, the Federal Circuit U.S. Court of Appeals agreed with the Patent Trial and Appeal Board that various claims of a patented apparatus that detects and controls the distance from the ground at which an agricultural machine operates would not have been obvious to a person of skill in the art.
ALEXANDRIA, Va. — Allegations that a porcine circovirus type 3 (PCV3) immunogenic composition represents an unpatentable law of nature will be heard by the Patent Trial and Appeal Board, which on Feb. 3 instituted post-grant review.
MARSHALL, Texas — Assertions by Apple Inc. that a patent owner is barred by estoppel from asserting that its encryption technology was infringed by the “Fair Play” digital rights management program were stricken Feb. 3 by a federal magistrate judge in Texas.
ALEXANDRIA, Va. — In a Feb. 2 petition for inter partes review filed with the Patent Trial and Appeal Board, R.J. Reynolds Vapor Co. maintains that a container for storing tobacco that features a lid and gasket for forming a non-hermetic seal “was well known in the art.”
ALEXANDRIA, Va. — A research organization on Feb. 1 told the Patent Trial and Appeal Board that it should cancel a patent that recites isolated nicotinamide riboside kinase (Nrk) nucleic acid sequences, vectors and cultured cells because what is claimed was “known, or would have been obvious, in view of the understanding of the art at the time of invention.”
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on Feb. 1 upheld a win for Samsung Electronics Co. Ltd., which prevailed before the Patent Trial and Appeal Board in an inter partes review (IPR) of a patent directed to a more efficient method for compressing video files,
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals in a Feb. 1 ruling upheld a determination by the Patent Trial and Appeal Board that four DNA sequencing patents owned by the trustees of Columbia University in New York are obvious.
WASHINGTON, D.C. — A mixed outcome in a post-grant review (PGR) was affirmed Jan. 28 by the Federal Circuit U.S. Court of Appeals, which agreed with the Patent Trial and Appeal Board that some claims of a patented hair treatment would have been obvious while others were not proven unpatentable.
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on Jan. 26 found that a federal judge in Delaware “correctly interpreted” a license agreement covering the code-division multiple access (CDMA) standard and that the agreement barred a patent owner’s allegations of infringement while the agreement was in effect.
SAN FRANCISCO — The developer of a mobile messaging app tells the Ninth Circuit U.S. Court of Appeals in a Jan. 19 reply brief that Apple Inc. cannot claim priority of use in the “Memoji” trademark, asking the court to reverse a trial court’s grant of summary judgment to Apple in a trademark infringement suit centering on the two companies’ competing Memoji apps.